目的:为明确我国医药产业今后发展的产业政策定位提供参考.方法:基于对医药产业集聚的必要性和对“火炬计划”中的国家级高新技术开发区和特色产业基地现状的了解,分析我国医药产业集聚的特点,进而探索优化我国医药产业集聚的策略.结果与结论:我国医药产业集聚中存在一些不利于长远发展的因素,如集聚领域方面多集中在生物制药领域,集聚特色需进一步开发；集聚进程方面多处于构建成长阶段,集聚优势未凸显；集聚的区位因子方面多由政府政策引导规划,市场属性需进一步强化.需要从集聚前的区位选择机制、集聚中产业领域选择以及集聚后区域产业升级3个阶段讲行针对性策略调整.%OBJECTIVE: To provide reference for the future development strategies of pharmaceutical industry in China. METHODS: Basing on the understanding on the necessity of pharmaceutical industrial agglomeration and the status quo of national high-tech development zones and characteristic industrial base of torch plan, the characteristics of pharmaceutical industrial agglomeration in China were analyzed so as to explore the effective strategies of optimizing pharmaceutical industry agglomeration. RESULTS & CONCLUSIONS: The pharmaceutical industrial agglomeration has some unfavorable factors to long-term development in China, I.g. Pharmaceutical industrial agglomeration mainly focuses on biological medicine production, and the characteristics of it should be developed further more; industrial agglomeration is on the construction and growth stage, the advantages of it haven't been revealed; the location factors of industrial agglomeration are mainly determined by policy and regulations, the marketability of it needs further enhancement. We should adjust the strategies from three stages, such as industrial location selection mechanism before industrial agglomeration, industry selection during industrial agglomeration and regional industrial upgrading after industrial agglomeration.
展开▼
